# Deliverable · Position Paper: Generative AI for Pharmacometrics (MCS Perspective)

**What:** Position paper articulating MCS's distinctive GenAI contribution — physics-constrained generation, synthetic data validation, and LLM failure modes. Covers Pillar 4.

**Target journal:** CPT: Pharmacometrics & Systems Pharmacology *or* Frontiers in Pharmacology
**Timeline:** Outline Month 8 · First draft Month 11 · Preprint Month 14

---

## Sub-tasks

### Setup
- [ ] Lock scope with cross-SIG alignment memo (from `community/`) before writing abstract
- [ ] `methods/04_generative_ai/` M4.4 scope differentiation memo must exist first
- [ ] Decide: standalone MCS paper, or co-developed with AI/ML SIG for LLM failure modes section?

### Abstract and scope statement
- [ ] Write 1-paragraph scope statement: what is in scope (physics constraints, synthetic validation, LLM failures) and explicitly what is out of scope (LLM literature mining, AI coding tools, molecular design)
- [ ] Draw from `methods/04_generative_ai/` M4.4 scope differentiation memo

### Section A — Physics-constrained generative models
*Draws from `methods/04_generative_ai/` M4.1*
- [ ] Define pharmacometric constraint types (mass balance, monotonicity, physiological bounds, identifiability)
- [ ] Enforcement strategies by model type: VAE, diffusion, LLM-generated ODE code
- [ ] Research agenda: what is tractable to enforce, what remains open
- [ ] Distinguish from PINN (physics-informed neural networks) literature — what's shared, what's new for pharmacometrics

### Section B — Mathematical validation of synthetic pharmacometric data
*Draws from `methods/04_generative_ai/` M4.2*
- [ ] Why marginal statistics are insufficient: joint correlation structure, dose-response trajectory shape
- [ ] Three-layer validation framework: statistical, pharmacological, identifiability
- [ ] Regulatory layer: mapping to FDA credibility framework for synthetic control arms
- [ ] Case material: De Carlo virtual patient generation and validation

### Section C — LLM failure mode taxonomy
*Draws from `methods/04_generative_ai/` M4.3*
- [ ] Six failure mode categories with illustrative examples (generated deliberately for the paper)
- [ ] Automated checker design: given an ODE system, flag each category
- [ ] Practical guidance: how should a pharmacometrician verify LLM-generated model code?
- [ ] Tool release: checker as open-source script accompanying the paper

### Review and submission
- [ ] Scope confirmed: Month 8 (prerequisite: cross-SIG alignment)
- [ ] Outline: Month 8
- [ ] First draft: Month 11
- [ ] Internal review: Month 12–13
- [ ] Preprint (bioRxiv): Month 14
- [ ] Journal submission: Month 15–16

---

## Key sources
| Source | Section(s) |
|---|---|
| `sources/papers/dermawan_2026.json` | A (VAE for NLME, neural PBPK) |
| `sources/background/aiml_claude_background.json` | A, C (GenAI survey) |
| `sources/background/aiml_chatgpt_background.json` | A (broader landscape) |
| `sources/papers/de_carlo_2024.json` | B (virtual patient validation) |
| `sources/papers/de_carlo_2025.json` | B (virtual patient validation) |
| `sources/web/fda_ai_guidance_2025.json` | B (regulatory criteria for synthetic data) |

## Dependencies
- `methods/04_generative_ai/` M4.1–M4.4 must be substantively in progress
- `community/` cross-SIG alignment: scope boundary with AI/ML SIG and QSP SIG required before abstract
- `deliverables/papers/whitepaper_hybrid/` Section D: coordinate on synthetic data overlap

## Open questions
- [ ] Section order: A (physics constraints, most mathematical) or C (LLM failures, most topical) first? Recommend A first — it is most distinctively MCS
- [ ] LLM failure modes: generate illustrative examples using Claude/GPT-4 for the paper? This would make the paper more concrete and immediately useful
- [ ] Release the LLM failure mode checker as an accompanying tool? Would significantly increase paper impact and citations
